Longevity is a Society‑Scale Problem
Living longer and healthier lives will have dramatic impacts on the economy beyond just biotech.
The argument on this page follows Omri Amirav-Drory’s essay Longevity Can Save America (NFX). Charts are the ones from the deck; each carries its source and date.
01 The bill
The National Debt Continues to Grow
Most of the gap between what the government spends and what it earns is non-discretionary: Medicare, Medicaid, Social Security, and interest on the debt itself.
In 2025, interest payments on the national debt were about $1.22 trillion, for the first time more than defense spending. NFX essay, citing federal budget figures.
$35.46 trillion in 2024, and growing.
Historical series, 1966 to 2024, as charted in the deck. Sources: Federal Reserve Bank of St. Louis, U.S. Department of the Treasury, Statista. The NFX essay puts the figure at $39.28 trillion as of June 2026; this chart stops at the deck’s last data point.
02 Where the money goes
Age-related illness is the biggest line in the healthcare bill.
Adults 65 and older are 18% of the population and account for 36% of healthcare spending, twice their share. Adults 19 to 34 are 21% of the population and 12% of the spending, about half their share.
The essay’s point: we are already spending this money, once people are sick. Longevity medicine is the attempt to keep people as healthy at 65 as they are at 19, so that spending moves from treatment to prevention. Shares of population and health spending by age group, 2021, as charted in the deck and cited in the essay.
People over 65 are 18% of the population and 36% of the spending.
Hover a band. Every age group under 55 spends less than its population share; everyone over 55 spends more. Source: as charted in the deck, 2021 data.
The retirement gap
The system was built for a two-to-five-year retirement.
When the U.S. set retirement in the mid-sixties, life expectancy was around 60. People now live roughly 15 to 20 years longer, but healthspan has not grown with it. The result is a 15-to-20-year dependency period instead of two to five, and progressively more expensive care across those years. Historical framing from the NFX essay; the essay does not cite a specific actuarial source for the figures.
What the essay does not claim
Longer lives alone don’t cut pension or debt costs.
The argument depends on healthier later life: people who keep working, earning and paying taxes rather than drawing down benefits. Longer lives without more healthy years would widen the gap, not close it.
03 Productive years and wealth accumulation
More healthy years means more years of earning, saving and investing.
The largest cohort of savers and investors today is people aged 50 to 65: mortgages paid, children grown, earning at their peak and spending less than they earn.
The essay’s scenario extends that phase by decades. If 70-year-olds had the capabilities of today’s 30-year-olds, they could keep contributing, paying taxes and building wealth instead of drawing down savings and benefits. Illustrative scenario from the NFX essay, not a forecast.
Money earned, by age: a normal and an extended wealth accumulation phase.
Illustrative curves as drawn in the deck. They show the shape of the argument, not measured earnings data.
Compressed morbidity: the sick years move to the very end.
Source: longevity.technology, as shown in the deck. A schematic of two life courses, not population data.
04 Broader economic effects
The essay’s chain: healthier people, more capital, cheaper debt, faster growth.
Each link is the essay’s reasoning. The numbers are modeled estimates, not realized growth.
- 1
A longer accumulation phase is a capital formation effect.
Money invested at 50 to be spent at 75 flows into bonds, stocks, pension funds and bank deposits in the meantime. More people with more wealth and more time to invest means more capital to deploy and, the essay argues, lower interest rates, including on the national debt.
- 2
Experienced workers stay in the workforce longer.
The essay’s scenario: people healthy and productive until 85 instead of retiring at 65 add 20 years of peak-productivity work from the people with the most accumulated expertise. Extended careers, lower healthcare spending, more consumer spending, more tax revenue and a smaller caregiving burden are the complementary effects it lists.
- 3
The modeled value is large.
The essay cites research estimating that slowing aging enough to add one year of life expectancy is worth about $38 trillion to the U.S., and ten years about $367 trillion; and a paper estimating that each year of life-expectancy gain generates value equal to 4 to 5% of annual GDP, repeating each year. These are economic-value models (the essay refers to “a recent paper” without naming it), not measured GDP growth or budget savings.
05 Fertility and family timing
Culture changed faster than biology.
The U.S. fertility rate hit a historic low in 2024, and the essay cites projections that by 2100 more than three-quarters of countries will be below replacement.
The essay’s reading: people now need advanced education, financial stability and affordable housing before starting a family, which pushes family timing past the peak fertility years of the twenties and early thirties. Its proposal is to extend the biological window so people can choose when to start a family. Fertility figures as cited in the NFX essay.
Research ambitions, not available treatments
The approaches the essay names are in research: genetically matched eggs from stem cells, better egg preservation and quality, and extending ovarian function.
None of these is presented as a clinical option today.
06 Investment and enabling conditions
None of it happens at today’s level of investment.
Aging research is critically underfunded, and the essay names four things that have to change for the benefits above to become possible.
0.5% of NIH. Under 1% of biotech valuation. Under 3% of biotech startup funding.
Sourced from Longevity Biotech Fellowship, as shown in the deck. The deck does not date these figures.
Government investment
Federal funding for longevity research at the NIH, FDA and ARPA-H for aging-targeted therapies, and Medicare coverage for proven longevity interventions.
Private capital
Venture capital, private equity and corporate R&D treating longevity as a high-return investment area.
Regulatory adaptation
A pathway to evaluate and approve treatments that target aging processes rather than only specific diseases.
Social infrastructure
Lifelong learning, employment policies that accommodate longer working lives, and communities designed for healthy aging.
The four conditions are the essay’s. Read the full argument: Longevity Can Save America.
Society’s choice
Spend trillions on early death
or
Make trillions on living longer lives.